Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07106892 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer

Name: Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer — clinical trial record (NCT07106892)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorShanghai Henlius Biotech

Started2025-09-15

View on ClinicalTrials.gov ↗

Amendment history

2025-11-14

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2025-08-15→confirmed 2025-09-15

Study sites1→2

2025-08-05

Original filing

Shanghai Henlius Biotech

56 trials monitored

See all monitored trials

Colorectal Cancer

2,904 trials monitored

See 127 trials at risk

The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Colorectal Cancer (CRC)

Trial Details

NCT Number	NCT07106892
Lead Sponsor	Shanghai Henlius Biotech
Conditions	Colorectal Cancer (CRC)
Enrollment	60 participants
Start Date	2025-09-15
Primary Completion	2026-12-30 (estimated)
Study Completion	2027-08-30 (estimated)
Updated on ClinicalTrials.gov	2025-11-17